Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in ACADIA Pharmaceuticals Inc., Celldex Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how ACADIA Pharmaceuticals Inc., Celldex Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About ACADIA Pharmaceuticals Inc., Celldex Therapeutics and Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer’s disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington’s disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Latest Biotechnology and ACADIA Pharmaceuticals Inc., Celldex Therapeutics, Inc. Stock News

As of July 30, 2026, ACADIA Pharmaceuticals Inc. had a $4.5 billion market capitalization, compared to the Biotechnology median of $251.9 million. ACADIA Pharmaceuticals Inc.’s stock is down 3.1% in 2026, up 4.1% in the previous five trading days and up 17.32% in the past year.

Currently, ACADIA Pharmaceuticals Inc.’s price-earnings ratio is 12.1. ACADIA Pharmaceuticals Inc.’s trailing 12-month revenue is $1.1 billion with a 34.3% net profit margin. Year-over-year quarterly sales growth most recently was 9.7%. Analysts expect adjusted earnings to reach $0.367 per share for the current fiscal year. ACADIA Pharmaceuticals Inc. does not currently pay a dividend.

As of July 30, 2026, Celldex Therapeutics, Inc. had a $3.0 billion market cap, putting it in the 60th percentile of all stocks. Celldex Therapeutics, Inc.’s stock is up 40.1% in 2026, up 7.9% in the previous five trading days and up 75.33% in the past year.

Currently, Celldex Therapeutics, Inc. does not have a price-earnings ratio. Celldex Therapeutics, Inc.’s trailing 12-month revenue is $0.9 million with a % net profit margin. As of July 30, 2026, Celldex Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.352 per share for the current fiscal year. Celldex Therapeutics, Inc. does not currently pay a dividend.

How We Compare ACADIA Pharmaceuticals Inc., Celldex Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at ACADIA Pharmaceuticals Inc., Celldex Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

ACADIA Pharmaceuticals Inc., Celldex Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
ACADIA Pharmaceuticals Inc.	ACAD	D
Celldex Therapeutics, Inc.	CLDX	na

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

ACADIA Pharmaceuticals Inc. has a Value Score of 24, which is Expensive. Celldex Therapeutics, Inc. does not have a meaningful Value Score.

The Value Stock Winner: No Clear Winner

Neither ACADIA Pharmaceuticals Inc., Celldex Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if ACADIA Pharmaceuticals Inc., Celldex Therapeutics or Inc. is the better investment when it comes to value.

ACADIA Pharmaceuticals Inc., Celldex Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
ACADIA Pharmaceuticals Inc.	ACAD	B
Celldex Therapeutics, Inc.	CLDX	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

ACADIA Pharmaceuticals Inc. has a Momentum Score of 62, which is Strong. Celldex Therapeutics, Inc. has a Momentum Score of 83, which is Very Strong.

The Momentum Grade Winner: Celldex Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Celldex Therapeutics, Inc. is considered to have stronger momentum compared to ACADIA Pharmaceuticals Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Celldex Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

ACADIA Pharmaceuticals Inc., Celldex Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
ACADIA Pharmaceuticals Inc.	ACAD	F
Celldex Therapeutics, Inc.	CLDX	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

ACADIA Pharmaceuticals Inc. has a Earnings Estimate Score of 17, which is Very Negative. Celldex Therapeutics, Inc. has a Earnings Estimate Score of 47, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither ACADIA Pharmaceuticals Inc., Celldex Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if ACADIA Pharmaceuticals Inc., Celldex Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other ACADIA Pharmaceuticals Inc., Celldex Therapeutics and Inc. Grades

In addition to Value, Estimate Revisions and Momentum, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether ACADIA Pharmaceuticals Inc., Celldex Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, ACADIA Pharmaceuticals Inc., Celldex Therapeutics or Inc. Stock?

Overall, ACADIA Pharmaceuticals Inc. stock has a Value Score of 24, Momentum Score of 62 and Estimate Revisions Score of 17.

Celldex Therapeutics, Inc. stock has a Value Score of , Momentum Score of 83 and Estimate Revisions Score of 47.

Comparing ACADIA Pharmaceuticals Inc., Celldex Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.